Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Medicus Pharma Ltd. (NASDAQ:MDCX) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 15 that MDCX announced the filing of a Rare Pediatric Disease Designation request with the U.S. Food and Drug Administration for SkinJect, its investigational doxorubicin-containing microneedle array patch, for the treatment of basal cell carcinoma in patients with Gorlin Syndrome.

The submission follows the company's previously filed Orphan Drug Designation application and ongoing FDA review of its registrational study design. MDCX reported that recent Phase 2 results demonstrated encouraging clinical and complete response rates while maintaining a favorable safety profile. If granted, the designation could support the company's regulatory strategy and potentially provide eligibility for a Rare Pediatric Disease Priority Review Voucher, subject to future FDA approval.

Separately, Medicus Pharma Ltd. (NASDAQ:MDCX) announced earlier on June 8 that it had filed a substantial modification application through the European Union CTIS for the planned Phase 2b study of Teverelix in advan

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/medicus-pharma-ltd-mdcx-stock-132036598.html)